FY2021 Briefing session regarding Life Sciences business(PDF:4,786KB)

JSR Life Sciences Business Review

December 8, 2021 (TOKYO)

1

Legends

• BPM: Bioprocess Materials
• CRO: Contract Research Organization
• CDMO: Contract Development and Manufacturing Organization
• IVD: in vitro Diagnostics
• CC182: JLS's internal drug repositioning program to demonstrate its integrated expertise and capabilities
• API: Active Pharmaceutical Ingredients
• HUB:Hubrecht Organoid Technology
• CMF: CDMO's new commercial manufacturing facility in NC, US (KBI)
• Geneva Expansion: CDMO's new clinical manufacturing facility in Geneva
• GPCR: G-protein-coupled receptors
• SUB: Single use bioreactor

*JLS:JSR Life Sciences

• BLA: Biologic License Application
• PDX: Patient derived xenograft
• CLD: Cell Line Development
• PD: Process Development
• CMC: Chemistry, Manufacturing and Control
• CMO: Contract Manufacturing Organization
• CDx: Companion Diagnostics
• MDx: Molecular Diagnostics
• PPQ: Process Performance Qualification
• BsAb、Bispecific Mabs: bispecific monoclonal antibody
• mAb: Monoclonal antibody
• CLIA: Clinical Laboratory Improvement Amendments
• NGS/AI: JLS Internal R&D project around genomic research
• MTP: Mid-term Business plan

2

JSR Group Management Policy

3

Summary of Management Policy

• Create value for all stakeholders through sustainable growth

Vision ● Strengthen the resilient business structure by responding to changes in the environment

	Business Portfolio		Business Target
Digital Solutions (especially SEMI)			more than
and Life Sciences as the center of	ROE
10%
	our business portfolio
	SEMI	Life Sciences			Exceed Prior
	Core OP	Peak

more than 600 Oku-yen

Digital Solutions &Life Sciences

Structure

Resilient

infrastructure

Innovation

Digitalization

ESG commitment

Employee engagement

4

Business Portfolio

Ave. ROIC FY'17-FY'20	**The size of circle;
35%	Ave. Core-OP in FY'17-FY'20

30%	Display &
Edge Computing
25%		SEMI
20%
15%

10%Plastics

5%				Life Sciences
Elastomers
0%
-15%	0% 5%	15%	25%
* Acquisition is included in revenue CAGR	Revenue CAGR FY'17-FY'20
of Plastics and Life Sciences

ROIC FY'24	**The size of circle; Core-OP in FY'24
	35%			Focus Businesses
	30%		SEMI
		Display &
	25%
		Edge Computing
	20%
	15%		Petro	Life
			Structural Reform	Sciences
	10%
5%

0%

0%

5%

10%

15%

20%

Revenue CAGR FY'21-FY'24

5